Syncona Share News (SYNC)

Syncona Information

Buy SYNC Shares
Add SYNC to Watchlist
Add SYNC to Alert

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 110.00

Bid: 0.00

Ask: 0.00

Change: 0.00 (0.00%)

Spread: 0.20 (0.182%)

Open: 0.00

High: 0.00

Low: 0.00

Prev. Close: 110.00

Last checked at -

Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

IN BRIEF: Syncona notes investee company's quarterly loss

Tue, 14th Nov 2023 11:29

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.

Current stock price: 127.32 pence, down 0.7%

12-month change: down 33%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

More News

17 Apr 2020 06:08

Syncona, Arix Note US FDA Acceptance Of Autolus Drug Application

31 Mar 2020 16:20

Director dealings: Syncona chair acquires shares

(Sharecast News) - Syncona revealed on Tuesday that chairperson Melanie Gee had acquired 26,500 ordinary shares in the FTSE 250-listed life sciences investor.

23 Mar 2020 09:36

Syncona flags delays to clinical programmes amid pandemic

(Sharecast News) - Syncona updated the market on its trading amid the Covid-19 coronavirus pandemic on Monday, reporting that since the start of the outbreak, it had taken measures to protect its employees, primarily centred around remote working, to help ensure it could continue to operate with as minimal disruption as possible.

23 Mar 2020 09:36

Syncona Expects Delays In Clinical Trials Due To Virus Disruption

20 Mar 2020 15:57

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

5 Mar 2020 15:41

DIRECTOR DEALINGS SUMMARY: IAG Chair And Director Spend EUR1.2 Million

24 Feb 2020 12:28

Monday broker round-up

(Sharecast News) - Rentokil: Jefferies upgrades to buy with a target price of 620p.

12 Feb 2020 15:35

Syncona Investee Presents Positive Data For Fabry, Gaucher Studies

7 Feb 2020 14:37

Syncona Investee Freeline Reports Positive Data From FLT180a Trial

4 Feb 2020 11:33

Syncona pleased at end of 'productive' quarter

(Sharecast News) - Healthcare investment company Syncona updated the market on the quarter ended 31 December on Tuesday, reporting that its had expanded, invested in and advanced its portfolio in the period.

4 Feb 2020 10:51

Syncona Net Assets Rise Slightly In "Productive" Third Quarter

30 Jan 2020 16:34

Syncona, Arix Note New Data From Autolus Trial Of AUTO3 Cell Therapy

23 Jan 2020 09:00

Syncona, Arix Note Pricing Of Public Offering By Autolus Therapeutics

23 Jan 2020 08:14

Syncona puts $15m into Autolus US offering

(Sharecast News) - Healthcare investment company Syncona announced on Thursday that its portfolio company, Autolus Therapeutics, had confirmed the pricing of its underwritten public offering in the United States.

19 Dec 2019 08:58

Latest Share Chat

Syncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

IN BRIEF: Syncona notes investee company's quarterly loss

Syncona, Arix Note US FDA Acceptance Of Autolus Drug Application

Director dealings: Syncona chair acquires shares

Syncona flags delays to clinical programmes amid pandemic

Syncona Expects Delays In Clinical Trials Due To Virus Disruption

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

DIRECTOR DEALINGS SUMMARY: IAG Chair And Director Spend EUR1.2 Million

Monday broker round-up

Syncona Investee Presents Positive Data For Fabry, Gaucher Studies

Syncona Investee Freeline Reports Positive Data From FLT180a Trial

Syncona pleased at end of 'productive' quarter

Syncona Net Assets Rise Slightly In "Productive" Third Quarter

Syncona, Arix Note New Data From Autolus Trial Of AUTO3 Cell Therapy

Syncona, Arix Note Pricing Of Public Offering By Autolus Therapeutics

Syncona puts $15m into Autolus US offering

Syncona Commits USD80 Million Investment Into Freeline Therapeutics

Latest Share Chat

Syncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Syncona notes investee company's quarterly loss

Login to your account

Quickpicks are a member only feature

Login to your account